The authors evaluate the role of prostate specific antigen (PSA) and bone scintigraphy in the follow-up of radical prostatectomy-treated and radiotherapy-treated patients. 784 patients were evaluated by simultaneous PSA assay and bone scans. The correlation between PSA levels and extension of bone metastases was good. The frequency of extraskeletal metastases was low: only 13 patients had soft tissue metastases without bone involvement and 33/138 patients with bone metastases had also extraskeletal metastases.
The results underline the importance of PSA and the possibility to omit bone scan when the PSA level is below 8 ng/ml in patients who did not undergo anti-androgenic treatments.
LeoM.E., BilhartzD.L., BergstrahlE.J., OesterlingJ.E.Prostate specific antigen in hormonally treated stage D2 prostate cancer: Is it always an accurate indicator of disease status?J Urol1991; 145: 802–6.
2.
StameyT.A., KabalinJ.N., FerrariM., YangN.Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients.J Urol1989; 141: 1088–90.
3.
OesterlingJ.E.Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.J Urol1991; 145: 907–23.
4.
GleaveM.E., CouplandD., DrachenburgD.. Ability of serum prostate specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer.Urology1996; 47: 708–12.
5.
ChybowskyF.M., Larson KellerJ.J., BergstrahlE.J., OesterlingJ.E.Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.J Urol1991; 145: 313–8.
6.
VijayakumarV., VijayakumarS., QuadriS.F., BlendM.J.Can prostate-specific antigen levels predict bone scan evidence of metastases in newly diagnosed prostate cancer?Am J Clin Oncol1994; 17: 432–6.
7.
TerrisM.K., KloneckeA.S., McDougallI.R., StameyT.A.Utilization of bone scan in conjuction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy.J Nucl Med1991; 32: 1713–7.
8.
FreitasJ.E., GilvydasR., FerryJ.D., GonzalezJ.A.The clinical utility of prostate-specific antigen and bone scintigraphy in prostate cancer follow-up.J Nucl Med1991; 32: 1387–90.
9.
SchultzeH., IsaacsJ.T.Biology and therapy of prostatic cancer.Cancer Surveys1986; 5(3): 79–94.
10.
FiggW.D., AmmermanK., PatronasN.. Lack of correlation between prostate-specific antigen and the presence of measureable soft tissue metastases in hormone-refractory prostate cancer.Cancer Invest1996; 14: 513–7.
11.
BruchowskyN., BrownE.M., CoppinC.M.. The endocrinology and treatment of prostate tumor progression. In: Current concepts and approaches to the study of prostate cancer.New York: Alan R Liss Inc, 1987; 347–87.
12.
StameyT.A., KabalinJ.N.Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients.J Urol1989; 141: 1070–5.
